The U.S. Food and Drug Administration has approved an expanded indication for Tzield (teplizumab-mzwv), allowing its use in children as young as one year old to delay the onset of stage 3 Type 1 Diabetes. Previously authorized for patients aged eight years and older, the decision marks a significant shift in early intervention strategies for the autoimmune condition.
The approval follows a priority review and is backed by data from the PETITE-T1D phase 4 clinical trial, which evaluated the therapy’s safety and pharmacokinetics in very young children diagnosed with stage 2 type 1 diabetes. The findings demonstrated that the treatment could be administered safely in this population, supporting its broader use.
Medical experts have highlighted the importance of early intervention in managing type 1 diabetes progression. Kimber Simmons, Associate Professor of Pediatrics at the Barbara Davis Center in Colorado, noted that the expanded approval could make a meaningful difference for families. She explained that children diagnosed at a very young age often face a higher and more unpredictable risk of progressing to stage 3 disease, where insulin dependence becomes unavoidable. Delaying this progression during early childhood—when disease management is particularly complex—could significantly ease the burden on caregivers.
From an industry perspective, the approval also underscores a growing focus on immune-based therapies. Christopher Corsico, Global Head of Development at Sanofi, emphasized that the autoimmune process behind type 1 diabetes frequently begins early in life. Targeting the immune system at these early stages may help preserve insulin production and alter the disease’s natural course.
Tzield is designed to modulate the immune response that attacks insulin-producing beta cells in the pancreas. By delaying this destruction, the therapy can postpone the onset of full-stage disease, reducing the immediate need for lifelong insulin therapy.
The treatment is also under review by the FDA for an additional indication—to delay progression in patients aged eight years and older who have recently been diagnosed with stage 3 type 1 diabetes. If approved, this could further broaden its clinical utility.
Globally, Tzield has already gained regulatory approvals in several regions. It is authorized in the European Union under the name Teizeild, as well as in countries including the United Kingdom, China, Canada, Brazil, and others, for delaying stage 3 onset in patients aged eight and above with stage 2 disease. Additional regulatory reviews are ongoing.
Tzield has previously received both breakthrough therapy and orphan drug designations from the FDA, recognizing its potential to address an unmet medical need in a relatively small patient population. The latest approval reinforces its role as a pioneering therapy in efforts to intervene earlier in the course of type 1 diabetes.